Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 239,843 shares of the medical equipment provider’s stock after selling 6,112 shares during the period. Gamco Investors INC. ET AL’s holdings in Zimmer Biomet were worth $23,625,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Legacy Wealth Asset Management LLC lifted its stake in Zimmer Biomet by 2.3% in the third quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after buying an additional 106 shares during the period. Global Retirement Partners LLC grew its position in shares of Zimmer Biomet by 7.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock worth $166,000 after buying an additional 111 shares during the period. Cullen Frost Bankers Inc. grew its position in shares of Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 116 shares during the period. Generali Asset Management SPA SGR increased its stake in shares of Zimmer Biomet by 0.9% in the 3rd quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock valued at $1,402,000 after acquiring an additional 122 shares during the last quarter. Finally, Brookstone Capital Management raised its position in shares of Zimmer Biomet by 1.3% in the 3rd quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock valued at $921,000 after acquiring an additional 123 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ZBH shares. UBS Group restated a “sell” rating and set a $89.00 price objective on shares of Zimmer Biomet in a report on Wednesday, February 11th. The Goldman Sachs Group lowered shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price on the stock. in a report on Friday, January 9th. Sanford C. Bernstein lifted their price target on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Robert W. Baird reissued a “neutral” rating and issued a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Price Performance

Shares of ZBH opened at $94.08 on Friday. The stock has a 50 day simple moving average of $92.13 and a 200 day simple moving average of $95.73. Zimmer Biomet Holdings, Inc. has a 52-week low of $84.59 and a 52-week high of $114.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The firm has a market capitalization of $18.41 billion, a PE ratio of 26.58, a P/E/G ratio of 1.91 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same period last year, the company posted $2.31 EPS. The business’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 27.12%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.